Apak-212 | __hot__

AKAP‑212 is a rationally engineered antimicrobial peptide that combines strong bactericidal activity against MDR Gram‑negative pathogens with excellent selectivity and in vivo efficacy. Its membrane‑active, toroidal pore mechanism reduces the likelihood of resistance development, positioning AKAP‑212 as a high‑value lead for further pre‑clinical development toward a novel class of anti‑infective agents.

1x APAK‑212 main unit 1x Protective carrying case 2x Rechargeable Li‑ion batteries (hot‑swappable) 1x Multi‑region power adapter Quick start guide & calibration tool APAK-212

is primarily recognized as a specific technical designation for the Altivar 212 Variable Speed Drive (VSD) produced by Schneider Electric . Hemolysis remained below 2 % even at 128

Hemolysis remained below 2 % even at 128 µg mL⁻¹ (32× MIC for the most resistant strain). Cytotoxicity assays indicated a therapeutic index >200. For decades, the TNI-AU relied on the Embraer

To understand the importance of the APAK-212, one must first understand the operational void it was designed to fill. For decades, the TNI-AU relied on the Embraer EMB-314 Super Tucano and the older BAE Hawk fleet for light attack and advanced training roles. However, the need for a modernized, more capable platform that could bridge the gap between basic training and high-intensity fighter jets became pressing. The APAK-212 program—centered around the procurement and adaptation of the KAI FA-50 (designated T-50 Golden Eagle in its trainer variant)—was the solution.

| | Result | |---------------|------------| | Peptide purity | 98.7 % (HPLC) | | Molecular mass | 2542.3 Da (observed 2542.5 Da) | | MIC (µg mL⁻¹) | A. baumannii : 0.5‑1; P. aeruginosa : 1‑2; K. pneumoniae : 2‑4; E. coli : 4‑8 | | Hemolysis @ 128 µg mL⁻¹ | 1.8 % | | IC₅₀ (HEK‑293) | 215 µg mL⁻¹ | | Calcein leakage (50 % release) | 2 µg mL⁻¹ peptide | | TEM observation | Disrupted outer membrane, cytoplasmic content leakage | | In vivo bacterial reduction | 3.6 log₁₀ CFU g⁻¹ vs. vehicle (p < 0.001) | | Serum stability (t½) | 6.5 h in 50 % human serum |